Previous close | 0.9861 |
Open | 0.9750 |
Bid | 0.8922 x 100 |
Ask | 0.9567 x 100 |
Day's range | 0.8995 - 0.9750 |
52-week range | 0.8500 - 2.0500 |
Volume | |
Avg. volume | 1,066,875 |
Market cap | 10.562M |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.1600 |
Earnings date | 11 Jul 2024 - 15 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.55 |
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to an aggregate of 6,562,500 shares of its
SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH). St
In this article, we will take a look at the top 15 3D printing companies in the US. If you want to skip our detailed analysis, you can go directly to Top 5 3D Printing Companies in the US. Recent Trends in 3D Printing According to a report by Grand View Research, the global 3D […]